ArticleThe Journal of nutrition2025
Effects of L-Arabinose on Glycemic Responses After the Consumption of Sucrose-Rich Foods in Individuals with Impaired Fasting Glucose: A Randomized Controlled Cross-Over Trial.
Article in The Journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImpaired fasting glucose (IFG) is considered a preclinical stage of type 2 diabetes. L-arabinose is a sucrase inhibitor that interferes with sucrose breakdown and has been shown to lower glycemic and insulinemic responses in healthy individuals. However, its effects in individuals with IFG are unknown.
objectivesThis study aims to assess effects of L-arabinose on glycemic responses after the consumption of sucrose-rich foods in individuals with IFG.
methodsEighteen adults [4 females, 14 males; age 73 ± 4 y; body mass index 27.5 ± 2.4 kg/m
resultsA single treatment of 10% w/w L-arabinose significantly reduced glucose peaks (-14%) and insulin peaks (-30%), with delays of 10 and 32 min, respectively. CGM also revealed significant reductions in variability compared with control value: standard deviation (-25%), coefficient of variation (-24%), and mean amplitude of glycemic excursions (-26%). However, no effects on glycemic variability were observed during the controlled diet.
conclusionsA single treatment of L-arabinose to a sucrose-rich drink reduced insulin and glucose responses in individuals with IFG, but this effect did not extend to a sucrose-rich diet containing complex meals and snacks. TRIAL REGISTRATION NUMBER: https://onderzoekmetmensen.nl/nl/trial/27001.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.